HERCEPTIN 600 MG VIAL

Purchase this product now and earn 14,750 Points!

Description

HERCEPTIN 600 MG VIAL

trastuzumab

herceptin

Indications of HERCEPTIN 600 MG VIAL

Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available “targeted” chemotherapies.  it is licensed for the treatment of the following:

  • HER2-positive breast canceradjuvant therapy – Approved for combination use with anthracycline- or taxane-based chemotherapy. The maximum recommended duration of adjuvant treatment is one year.
  • Metastatic HER2-positive breast cancer – Approved as monotherapy or for combination use with paclitaxel.
  • HER2-positive gastric cancer – Used in combination with cisplatin-based chemotherapy. Compared with chemotherapy alone, trastuzumab plus chemotherapy modestly improved survival (median 13.8 months vs. 11.1 months)

Trastuzumab has been reported efficacy for the off-label neoadjuvant treatment of HER2-positive breast cancer. For the treatment of metastatic breast cancer, trastuzumab has also been used in combination with lapatinib, anastrozole, cyclophosphamide, pertuzumab, and several other agents

 

Contraindications of HERCEPTIN 600 MG VIAL

  • Pregnancy: Trastuzumab is believed to be a human teratogen. Fetal exposure has been associated with the development of oligohydramnios, leading to pulmonary hypoplasia and death. Patients of childbearing potential should use at least one form of contraception while receiving trastuzumab. It is unknown if trastuzumab is secreted in human breast milk.
  • Cardiac Dysfunction: Due to the risk of cardiotoxicity, trastuzumab should be used with extreme caution in patients with pre-existing structural heart disease.

Continuing Education Activity of HERCEPTIN 600 MG VIAL

Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies. In the United States, it has FDA-approval for the treatment of HER2-positive breast cancer as adjuvant therapy in combination with anthracycline- or taxane-based chemotherapy, metastatic HER2-positive breast cancer as monotherapy, or for combination use with paclitaxel, and HER2-positive gastric cancer in combination with cisplatin-based chemotherapy. It also has off-label use in other HER2-positive cancers. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring, of trastuzumab so providers can direct patient therapy where it is indicated as part of the interprofessional team.

Objectives:

  • Identify the mechanism of action of trastuzumab.
  • Outline the possible combination therapies approved for trastuzumab.
  • Review the potential adverse effects of therapy with trastuzumab.
  • Explain interprofessional team strategies for improving care coordination and communication to properly use trastuzumab to improve patient outcomes when necessary for therapy.

 

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “HERCEPTIN 600 MG VIAL”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
🏷️ WANT A COUPON
Give us a review on Google or Facebook
Google Review

Facebook Review
and Subscribe now to get free discount coupon code. Don't miss out

    SUBSCRIBE